Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.76 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.76 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.76 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.76 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.76 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.76 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.76 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.76 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.76 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | NQO2 | P16083 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2781680 | 0.99 | HDAC6 (0.74) | HDAC6HDAC1HDAC3HDAC4HDAC2 | |
| SCHEMBL12973509 | 0.96 | HDAC6 (0.71) | HDAC6HDAC1HDAC3HDAC4HDAC2 | |
| SCHEMBL16866953 | 0.96 | HDAC6 (0.73) | HDAC6HDAC1HDAC3HDAC4HDAC2 | |
| SCHEMBL16866946 | 0.94 | HDAC6 (0.69) | HDAC6HDAC1HDAC3HDAC4HDAC2 | |
| SCHEMBL14823504 | 0.92 | HDAC6 (0.73) | HDAC6HDAC1HDAC3HDAC4HDAC2 | |
| SCHEMBL16754938 | 0.92 | HDAC6 (0.64) | HDAC6HDAC1HDAC3HDAC4HDAC2 | |
| SCHEMBL15690680 | 0.91 | HDAC6 (0.72) | HDAC6HDAC1HDAC3HDAC4HDAC2 | |
| SCHEMBL31688425 | 0.91 | HDAC6 (0.62) | HDAC6HDAC1HDAC3HDAC4HDAC2 | |
| SCHEMBL365881 | 0.91 | HDAC6 (0.62) | HDAC6HDAC1HDAC3HDAC4HDAC2 | |
| SCHEMBL9966133 | 0.90 | HDAC6 (0.79) | HDAC6HDAC1HDAC3HDAC4HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11844784-B2 | Stable pharmaceutical compositions of bendamustine | SLAYBACK PHARMA LLC (US) | 2023-12-19 | — | — | US | disclosed |
| US-20230364017-A1 | BENDAMUSTINE SOLID DISPERSIONS AND CONTINUOUS INFUSION | VOUDOURIS VASILIOS (US) | 2023-11-16 | — | — | US | disclosed |
| WO-2023213445-A1 | METHOD FOR PREPARING 4-[5-[BIS(2-CHLOROETHYL)AMINO]-1-METHYL-1H-BENZO[D]IMIDAZOL-2-YL]BUTYRIC ACID ALKYL ESTERS AND FORMYLATED DERIVATIVES | Heraeus Deutschland GmbH & Co. KG (DE) | 2023-11-09 | — | — | WO | disclosed |
| US-20230310384-A1 | STABLE PHARMACEUTICAL COMPOSITIONS OF BENDAMUSTINE | SLAYBACK PHARMA LLC (US) | 2023-10-05 | — | — | US | disclosed |
| US-20230310384-A1 | STABLE PHARMACEUTICAL COMPOSITIONS OF BENDAMUSTINE | SLAYBACK PHARMA LLC (US) | 2023-10-05 | — | — | US | disclosed |
| US-20230310381-A1 | BENDAMUSTINE PHARMACEUTICAL COMPOSITIONS | VOUDOURIS VASILIOS (US) | 2023-10-05 | — | — | US | disclosed |
| EP-3043648-B1 | BENDAMUSTINE PHARMACEUTICAL COMPOSITIONS | VOUDOURIS VASILIOS (US) | 2023-09-20 | — | — | EP | disclosed |
| US-11707450-B1 | Stable pharmaceutical compositions of bendamustine | SLAYBACK PHARMA LLC (US) | 2023-07-25 | — | — | US | disclosed |
| US-11707450-B1 | Stable pharmaceutical compositions of bendamustine | SLAYBACK PHARMA LLC (US) | 2023-07-25 | — | — | US | disclosed |
| US-11701344-B2 | Bendamustine pharmaceutical compositions | VOUDOURIS VASILIOS (US) | 2023-07-18 | — | — | US | disclosed |
| US-20130123316-A1 | Bendamustine Pharmaceutical Compositions | CEPHALON LLC | 2013-05-16 | — | — | US | disclosed |
| US-20130123316-A1 | Bendamustine Pharmaceutical Compositions | CEPHALON LLC | 2013-05-16 | — | — | US | disclosed |
| US-8436190-B2 | Bendamustine pharmaceutical compositions | CEPHALON, INC. (US) | 2013-05-07 | — | — | US | disclosed |
| WO-2013046223-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF BENDAMUSTINE HYDROCHLORIDE | FRESENIUS KABI ONCOLOGY LTD. (IN) | 2013-04-04 | — | — | WO | disclosed |
| EP-2574334-A1 | Bendamustine pharmaceutical compositions for lyophilisation | CEPHALON, INC. (US) | 2013-04-03 | — | — | EP | disclosed |
| US-20120165543-A1 | PROCESS FOR THE PRODUCTION OF BENDAMUSTINE ALKYL ESTER, BENDAMUSTINE, AND DERIVATIVES THEREOF | HERAEUS PRECIOUS METALS GMBH & CO. KG (DE) | 2012-06-28 | — | — | US | disclosed |
| EP-2468716-A1 | Process for producing bendamustine alkyl esters, bendamustine and derivatives of same | Heraeus Precious Metals GmbH & Co. KG (DE) | 2012-06-27 | — | — | EP | disclosed |
| US-20120003305-A1 | Oral Dosage Forms Of Bendamustine | ASTELLAS DEUTSCHLAND GMBH (DE) | 2012-01-05 | — | — | US | disclosed |
| US-20120003309-A1 | Solid Dosage Forms Of Bendamustine | ASTELLAS DEUTSCHLAND GMBH (DE) | 2012-01-05 | — | — | US | disclosed |
| WO-2010144675-A1 | POLYMORPHS OF BENDAMUSTINE HCL AND PROCESSES FOR PREPARATION THEREOF | PLUS CHEMICALS SA (CH) | 2010-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120003305-A1 | Oral Dosage Forms Of Bendamustine | TAS2R42, TAS2R40, TAS2R45 | HDAC6 1882/4885HDAC1 2640/4885HDAC3 2999/4885 |
| US-20120165543-A1 | PROCESS FOR THE PRODUCTION OF BENDAMUSTINE ALKYL ESTER, BENDAMUSTINE, AND DERIVATIVES THEREOF | OTC, OAT, BCKDK | HDAC6 1763/4885HDAC1 2804/4885HDAC3 2766/4885 |
| US-20230310384-A1 | STABLE PHARMACEUTICAL COMPOSITIONS OF BENDAMUSTINE | SORD, NONO, SBDS | HDAC6 1384/4885HDAC1 3398/4885HDAC3 3707/4885 |
| US-11707450-B1 | Stable pharmaceutical compositions of bendamustine | SORD, NONO, SBDS | HDAC6 1270/4885HDAC1 3593/4885HDAC3 3810/4885 |
| US-11844784-B2 | Stable pharmaceutical compositions of bendamustine | SORD, NONO, SBDS | HDAC6 1384/4885HDAC1 3398/4885HDAC3 3707/4885 |
| US-20230310381-A1 | BENDAMUSTINE PHARMACEUTICAL COMPOSITIONS | FLT3, BLK, FOLR2 | HDAC6 1308/4885HDAC1 3917/4885HDAC3 4356/4885 |
| US-11701344-B2 | Bendamustine pharmaceutical compositions | FLT3, BLK, FOLR2 | HDAC6 1308/4885HDAC1 3917/4885HDAC3 4356/4885 |
| US-20130123316-A1 | Bendamustine Pharmaceutical Compositions | FOLR1, FPGS, FLT3 | HDAC6 487/4885HDAC1 3095/4885HDAC3 3718/4885 |
| US-20120003309-A1 | Solid Dosage Forms Of Bendamustine | SORD, SI, SELL | HDAC6 122/4885HDAC1 182/4885HDAC3 428/4885 |
| US-20230364017-A1 | BENDAMUSTINE SOLID DISPERSIONS AND CONTINUOUS INFUSION | WEE1, SLC29A2, SLC29A1 | HDAC6 1618/4885HDAC1 2772/4885HDAC3 4295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.